Uscom Limited (UCM) AI Stock Analysis

• Market Cap: AU$5.76M
• Dividend Yield: N/A
• Average Volume (3M): 30.46K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.53
• Revenue Growth: 2.91%
• EPS Growth: 13.51%
• Country: AU
• Employees: 35
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 250,477,000
• 10 Day Avg. Volume: 28,694
• 30 Day Avg. Volume: 30,464
• PEG Ratio: 0.08
• Price to Book (P/B): 2.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Uscom Limited faces significant challenges, with financial performance being the primary concern due to ongoing profitability issues despite revenue growth. The technical analysis indicates a bearish trend, further compounded by a negative valuation outlook due to the negative P/E ratio. The stock is currently oversold, suggesting potential for a short-term technical rebound, but fundamental improvements are needed for sustained growth.

Uscom Limited Business Overview & Revenue Model

Company Description

Uscom Limited (UCM) is a medical technology company focused on developing and marketing innovative non-invasive devices for cardiovascular and respiratory health assessment. The company operates primarily in the healthcare sector, providing advanced diagnostic solutions to improve patient outcomes and support clinical decision-making. Uscom's core products include the Uscom 1A, a hemodynamic monitor, and the BP+ and SpiroSonic series, which offer blood pressure and spirometry measurements, respectively.

How the Company Makes Money

Uscom Limited generates revenue through the sale of its medical devices to hospitals, clinics, and healthcare providers globally. The company also earns income from service contracts, maintenance agreements, and software upgrades associated with its products. Key revenue streams include direct sales, distributor partnerships, and government contracts, which help expand its market reach. Additionally, Uscom may benefit from strategic collaborations with research institutions and healthcare organizations, further enhancing its product offerings and market penetration.

Uscom Limited Financial Statement Overview

Summary

Uscom Limited is experiencing growth in revenue, but ongoing profitability issues are a significant concern. The company's leverage is manageable, but declining equity ratios and negative cash flow metrics indicate potential financial instability. Continued efforts to improve profitability and cash flow management are essential for future growth.

Income Statement

Uscom Limited shows a fluctuation in its revenue, with a notable increase in the recent year. However, the company has consistently reported negative EBIT and net income, indicating ongoing profitability challenges. While the gross profit has improved, the net profit margin remains negative, which is a significant concern.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, suggesting manageable leverage levels. However, the equity ratio has been declining, indicating potential risks in asset management. The return on equity has been negative, highlighting the company's struggle to generate profit from its equity base.

Cash Flow

Cash flow analysis reveals persistent negative free cash flow, though operating cash flow has shown some improvement in recent periods. The free cash flow to net income ratio remains unfavorable, suggesting that the company is facing challenges in converting profits into cash.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
3.63M	3.73M	2.66M	2.51M	3.86M	3.48M
	Gross Profit
3.04M	3.12M	-1.03M	-1.21M	781.70K	458.00K
	EBIT
-2.70M	-2.38M	-2.92M	-2.61M	-1.43M	-1.80M
	EBITDA
-2.09M	-1.51M	-2.53M	-1.84M	-833.84K	-672.88K
	Net Income Common Stockholders
-2.36M	-2.07M	-2.59M	-1.97M	-924.24K	-1.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.16M	2.52M	2.18M	4.70M	1.71M	1.92M
	Total Assets
4.64M	5.13M	5.18M	7.99M	5.33M	5.92M
	Total Debt
1.86M	989.28K	1.09M	1.31M	1.43M	1.62M
	Net Debt
-302.08K	-1.53M	-787.15K	-376.91K	-265.40K	-288.21K
	Total Liabilities
2.76M	2.07M	2.14M	2.06M	2.26M	2.50M
	Stockholders Equity
1.88M	3.06M	3.04M	5.94M	3.08M	3.42M
Cash Flow		Free Cash Flow
-1.52M	-1.22M	-1.58M	-1.08M	21.63K	-321.38K
	Operating Cash Flow
-1.51M	-1.16M	-1.42M	-967.51K	54.98K	-283.23K
	Investing Cash Flow
-56.85K	-57.55K	-151.94K	-115.31K	-33.35K	-38.16K
	Financing Cash Flow
536.63K	1.57M	-952.96K	4.05M	-281.87K	1.03M

Uscom Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 21.68 is Positive, neither overbought nor oversold. The STOCH value of -9.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.

Uscom Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	79 Outperform	AU$55.94B	27.90	25.23%	0.82%	10.54%	38.69%
RHT	64 Neutral	AU$17.93M	140.00	-3.11%	―	89.13%	69.57%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.50%
IPD	49 Neutral	$66.91M	―	-51.08%	―	10.22%	-2.94%
MX1	47 Neutral	AU$40.02M	―	-135.33%	―	-27.58%	33.69%
UCM	46 Neutral	AU$5.76M	―	-117.20%	―	2.91%	13.51%
NXS	39 Underperform	$28.92M	―	-130.18%	―	3.37%	47.32%

Uscom Limited Corporate Events

Uscom Limited Reports Increased Revenue Amid Global Challenges

Uscom Limited released its quarterly cash report for the period ending March 31, 2025, showing a 14% increase in customer receipts compared to the previous quarter, despite a challenging global trade environment. The company’s operational highlights include significant clinical achievements, strengthened partnerships with Foxconn and SinoPharm, and the establishment of a new subsidiary in China to support expansion. With new products and strategic partnerships, Uscom is well-positioned for growth in anticipation of a more stable global economic environment.

Uscom Limited Reports Increased Losses Amid Revenue Decline

Uscom Limited reported a 5% decline in revenue and other income for the half-year ending December 31, 2024, totaling $1,859,295. The company’s net loss attributable to members increased by 32% to $1,188,595, and no dividend is proposed. The financial results highlight challenges in maintaining revenue levels and managing operational losses, impacting its financial position and potentially influencing stakeholder confidence.